[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356311-105":59,"doc-detail-356311-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","sarcopenia-myosteatosis-and-systemic-immunoinflammatory-index-in-the-prediction-of-survival-in-patients-undergoing-immunotherapy-for-esophageal-cancer","Sarcopenia, myosteatosis and systemic immunoinflammatory index in the prediction of survival in patients undergoing immunotherapy for esophageal cancer","","Survival prediction in esophageal cancer treated with immune checkpoint inhibitors focuses increasingly on sarcopenia, myosteatosis, and the systemic immune-inflammatory index (SII). A retrospective cohort of 178 patients receiving immunotherapy and CT imaging was analyzed to identify optimal survival thresholds for skeletal muscle density, skeletal muscle index, and SII. Cox regression and survival-curve analyses assessed overall survival and progression-free survival, with Fine-Gray competing-risk methods for OS. Sarcopenia, myosteatosis, and high SII independently predicted poorer OS and were integrated into an SMI-SMD-SII score, supporting risk stratification and guiding personalized treatment.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/sarcopenia-myosteatosis-and-systemic-immunoinflammatory-index-in-the-prediction-of-survival-in-patients-undergoing-immunotherapy-for-esophageal-cancer/356311/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/sarcopenia-myosteatosis-and-systemic-immunoinflammatory-index-in-the-prediction-of-survival-in-patients-undergoing-immunotherapy-for-esophageal-cancer/356311.png","ImageObject",300,407,{"name":92,"@type":93},"Eliana","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-19","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What was the study’s main purpose in esophageal cancer patients receiving immunotherapy?","Question",{"text":112,"@type":113},"To evaluate whether sarcopenia, myosteatosis, and the systemic immune-inflammatory index (SII) can predict survival outcomes in patients treated with immune checkpoint inhibitors.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were thresholds for skeletal muscle parameters and SII determined?",{"text":117,"@type":113},"Optimal survival thresholds for skeletal muscle density (SMD), skeletal muscle index (SMI), and SII were determined using X-tile plots.",{"name":119,"@type":110,"acceptedAnswer":120},"Which factors independently predicted overall survival, and how did PFS relate?",{"text":121,"@type":113},"Sarcopenia, myosteatosis, and high SII were independent risk factors for overall survival, while no independent association was found for progression-free survival (PFS).",{"name":123,"@type":110,"acceptedAnswer":124},"What does the SMI-SMD-SII score add to survival prediction?",{"text":125,"@type":113},"A composite SMI-SMD-SII score was established, and patients with score ≥ 2 had significantly shorter overall survival than those with score 0 or 1.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},356311,1790156232,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":19,"preview_urls":150},4398048949847,"https://ap-avatar.wpscdn.com/avatar/400002536579ef2da7f?_k=1778318612642679267","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nSarcopenia, myosteatosis and systemic immunoinflammatory index in the prediction of survival in patients undergoing immunotherapy for esophageal cancer  \nYanjing Zeng1,4, Jinmei Chen2,4, Liuyu Li1,4, Xinpeng Wang1, Ying Ye1, Tingjie Xiong1, Wenmin Ying3􀀍 & Zhichao Fu1􀀍  \nSurvival prediction in patients with esophageal cancer is receiving a lot of attention from sarcopenia, myosteatosis, and systemic immune-inflammatory index (SII). The aim of this study was to investigate the survival prediction value of these parameters in esophageal cancer patients treated with immune checkpoint inhibitors (ICIs). Retrospective analysis of 178 patients with esophageal cancer who received immunotherapy and CT imaging. X-tile plots were utilized to determine optimal survival thresholds for skeletal muscle density (SMD), skeletal muscle index (SMI), and SII. The relationship between these parameters and patients’ overall survival (OS) and progression-free survival (PFS) was explored by Cox regression modeling and survival curve analysis. For OS, the Fine-Gray test was used to analyze competing risks. In addition, correlation and interaction analyses were performed on these indicators. Sarcopenia (mOS 10.3 months vs. 23.6 months; P \u003C 0.001), and myosteatosis (mOS 13.0 months vs. 23.4 months; P = 0.008), high SII (14.4 months vs. 40.7 months; P = 0.002) were associated with poor OS. Multifactorial regression showed that sarcopenia (HR: 2.15; 95%CI:  \n1.19 ~ 3.88; P = 0.012), myosteatosis (HR: 2.34; 95%CI: 1.31 ~ 4.18; P = 0.004), and high SII (HR: 1.91; 95%CI: 1.15 ~ 3.18; P = 0.013) were the independent risk factors for OS in patients with esophageal cancer, but not for PFS. No significant association was found between sarcopenia, myosteatosis, ora high SII and non-cancer mortality in the competing risk model. In addition, there was a low positive correlation (r = 0.219, P = 0.004) and interaction (p = 0.008) between sarcopenia and myosteatosis. The SMI-SMD-SII score was established, and OS was significantly shorter in patients with score ≥ 2 than in patients with score = 0 and 1 (p \u003C 0.001). This study found that sarcopenia, myosteatosis, and SII correlate significantly with survival in patients with advanced esophageal cancer receiving immunotherapy. However, the OS-PFS discrepancy may be confounded by subsequent therapies and does not directly reflect initial efficacy. Prospective studies are needed to validate these findings and inform personalized treatment.  \nKeywords Esophageal cancer, Immunotherapy, Sarcopenia, Myosteatosis, Systemic immune-inflammatory index, Prognosis  \nSarcopenia, a disease characterized by a reduction in skeletal muscle mass and function, has become an important predictor of clinical prognosis in several cancers. Myosteatosis, manifested as a decrease in skeletal muscle radiodensity (SMD), reflects fatty infiltration in the muscle. SMD assessed by CT is strongly correlated  \n1Department of Radiotherapy, Fuzong Clinical Medical College (900 th Hospital), Fujian Medical University, Fuzhou 350025, Fujian Province, China. 2Key Laboratory of Radiation Biology of Fujian Higher Education Institutions, The First Affiliated Hospital, Fujian Medical University, 20 Cha-Zhong Road, Taijiang District, Fuzhou 350005, China.  \n3Department of Radiotherapy, Fuding Hospital, Fuding 355200, Fujian Province, China. 4Yanjing Zeng, Jinmei Chen and Liuyu Li contributed equally to this work. 􀀍 [email: ywm15080015210@163.com](email: ywm15080015210@163.com); [fauster1112@126.com](fauster1112@126.com)  \n[www. nature.com/scientificreports/](www. nature.com/scientificreports/)  \nwith physical function and can more effectively identify the risk of dysfunction1. Based on the guidelines of the European Consensus2, it was necessary in this study to have explored simultaneously the reduction in muscle number, the loss of muscle mass, and their impact on muscle function fo","cbCaiiNWBvBM6yD4","https://ap.wps.com/l/cbCaiiNWBvBM6yD4","pdf",3629067,14,"English","# Background\n## Muscle depletion, sarcopenia, and myosteatosis in cancer prognosis\n## Immune checkpoint inhibitors and the need for predictive biomarkers\n# Study Design\n## Retrospective cohort and CT-based body composition assessment\n## Determining survival thresholds with X-tile\n# Statistical Analysis\n## Associations with overall survival and progression-free survival\n## Cox regression, survival curves, and Fine-Gray competing risks\n## Correlation and interaction analyses\n# Results\n## Effects of sarcopenia, myosteatosis, and SII on OS and PFS\n## Competing-risk findings for non-cancer mortality\n## The SMI-SMD-SII score and survival stratification\n# Discussion and Conclusion\n## Clinical implications and need for prospective validation","[{\"question\":\"What was the study’s main purpose in esophageal cancer patients receiving immunotherapy?\",\"answer\":\"To evaluate whether sarcopenia, myosteatosis, and the systemic immune-inflammatory index (SII) can predict survival outcomes in patients treated with immune checkpoint inhibitors.\"},{\"question\":\"How were thresholds for skeletal muscle parameters and SII determined?\",\"answer\":\"Optimal survival thresholds for skeletal muscle density (SMD), skeletal muscle index (SMI), and SII were determined using X-tile plots.\"},{\"question\":\"Which factors independently predicted overall survival, and how did PFS relate?\",\"answer\":\"Sarcopenia, myosteatosis, and high SII were independent risk factors for overall survival, while no independent association was found for progression-free survival (PFS).\"},{\"question\":\"What does the SMI-SMD-SII score add to survival prediction?\",\"answer\":\"A composite SMI-SMD-SII score was established, and patients with score ≥ 2 had significantly shorter overall survival than those with score 0 or 1.\"}]","Sarcopenia, myosteatosis and systemic immunoinflammatory index in the prediction of survival in patients undergoing immunotherapy for esophageal cancer | PDF",1790124597,35,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/adb2e7e15d0ae2bfdce03c6353cd8a50.webp",983,1291,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c39ec649017bd4a597c31e3aa7e82da8.webp",982,1290,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a62a992a156997333cb381fc8d2c6909.webp",981,1289,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c5716a87c4a334ff00aab78b9da12b48.webp",980,1287]